|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, SteliarovaFoucher E,
LortetTieulent J, Rosso S, Coebergh JW, Comber H, Forman D and Bray
F: Cancer incidence and mortality patterns in Europe: Estimates for
40 countries in 2012. Eur J Cancer. 49:1374–1403. 2011. View Article : Google Scholar
|
|
3
|
Agudo A, Bonet C, Travier N, González CA,
Vineis P, Bueno-de-Mesquita HB, Trichopoulos D, Boffetta P,
Clavel-Chapelon F, Boutron-Ruault MC, et al: Impact of cigarette
smoking on cancer risk in the European prospective investigation
into cancer and nutrition study. J Clin Oncol. 30:4550–4557. 2011.
View Article : Google Scholar
|
|
4
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment and survivorship. Mayo Clin Proc. 83:584–594.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Suda K, Tomizawa K and Mitsudomi T:
Biological and clinical significance of KRAS mutations in
lung cancer: An oncogenic driver that contrasts with EGFR
mutation. Cancer Metastasis Rev. 29:49–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
MunfusMcCray D, Harada S, Adams C, Askin
F, Clark D, Gabrielson E and Li QK: EGFR and KRAS
mutations in metastatic lung adenocarcinomas. Hum Pathol.
42:1447–1453. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Sciences. 304:1497–1500. 2004.
View Article : Google Scholar
|
|
9
|
Pao W, Miller V, Zakowski M, Doherty J,
Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al:
EGF receptor gene mutations are common in lung cancers from ‘never
smokers’ and are associated with sensitivity of tumors to gefitinib
and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gazdar AF: Activating and resistance
mutations of EGFR in non-small-cell lung cancer: Role in
clinical response to EGFR tyrosine kinase inhibitors.
Oncogene. 28 Suppl 1:S24–S31. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kosaka T, Yatabe Y, Endoh H, Kuwano H,
Takahashi T and Mitsudomi T: Mutations of the epidermal growth
factor receptor gene in lung cancer: Biological and clinical
implications. Cancer Res. 64:8919–8923. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chougule A, Prabhash K, Noronha V, Joshi
A, Thavamani A, Chandrani P, Upadhyay P, Utture S, Desai S,
Jambhekar N, et al: Frequency of EGFR mutations in 907 lung
adenocarcioma patients of Indian ethnicity. PLoS One. 8:2013.
View Article : Google Scholar
|
|
13
|
Roberts PJ, Stinchcombe TE, Der CJ and
Socinski MA: Personalized medicine in non-small-cell lung cancer:
Is KRAS a useful marker in selecting patients for epidermal
growth factor receptor-targeted therapy? J Clin Oncol.
28:4769–4777. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pao W, Wang TY, Riely GJ, Miller VA, Pan
Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG and Varmus HE:
KRAS mutations and primary resistance of lung
adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2:e172005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eberhard DA, Johnson BE, Amler LC, Goddard
AD, Heldens SL, Herbst RS, Ince WL, Jänne PA, Januario T, Johnson
DH, et al: Mutations in the epidermal growth factor receptor and in
KRAS are predictive and prognostic indicators in patients
with non-small-cell lung cancer treated with chemotherapy alone and
in combination with erlotinib. J Clin Oncol. 23:5900–5909. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Riely GJ, Kris MG, Rosenbaum D, Marks J,
Li A, Chitale DA, Nafa K, Riedel ER, Hsu M, Pao W, et al: Frequency
and distinctive spectrum of KRAS mutations in never smokers
with lung adenocarcinoma. Clin Cancer Res. 14:5731–5734. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lindeman NI, Cagle PT, Beasley MB, Chitale
DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS,
Squire J, et al: Molecular testing guideline for selection of lung
cancer patients for EGFR and ALK tyrosine kinase inhibitors:
Guideline from the college of American pathologists, international
association for the study of lung cancer and association for
molecular pathology. Arch Pathol Lab Med. 137:828–860. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ellison G, Zhu G, Moulis A, et al:
EGFR mutation testing in lung cancer: A review of available
methods and their use for analysis of tumour tissue and cytology
samples. J Clin Pathol. 66:79–89. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Do H, Krypuy M, Mitchell PL, et al: High
resolution melting analysis for rapid and sensitive EGFR and
KRAS mutation detection in formalin fixed paraffin embedded
biopsies. BMC Cancer. 8:1422008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Krypuy M, Newnham GM, Thomas DM, et al:
High resolution melting analysis for the rapid and sensitive
detection of mutations in clinical samples: KRAS codon 12
and 13 mutations in non-small cell lung cancer. BMC Cancer.
6:2952006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pham D, Kris MG, Riely GJ, et al: Use of
cigarette smoking history to estimate the likelihood of mutations
in epidermal growth factor receptor gene exons 19 and 21 in lung
adenocarcinomas. J Clin Oncol. 24:1700–1704. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ahrendt SA, Decker PA, Alawi EA, et al:
Cigarette smoking is strongly associated with mutation of the K-ras
gene in patients with primary adenocarcinoma of the lung. Cancer.
92:1525–1530. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wong SQ, Li J, Tan AY, et al: CANCER 2015
Cohort: Sequence artefacts in a prospective series of
formalin-fixed tumours tested for mutations in hotspot regions by
massively parallel sequencing. BMC Med Genomics. 7:232014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Meldrum C, Doyle MA and Tothill RW:
Next-generation sequencing for cancer diagnostics: A practical
perspective. Clin Biochem Rev. 32:177–195. 2011.PubMed/NCBI
|
|
25
|
Szumera-Ciećkiewicz A, Olszewski WT,
Tysarowski A, Kowalski DM, Głogowski M, Krzakowski M, Siedlecki JA,
Wągrodzki M and Prochorec-Sobieszek M: EGFR mutation testing
on cytological and histological samples in non-small cell lung
cancer: A Polish, single institution study and systematic review of
European incidence. Int J Clin Exp Pathol. 6:2800–2812.
2013.PubMed/NCBI
|
